11 May 2016 - The Cleveland Clinic is widely seen as the top heart hospital in the country, so when Valeant Pharmaceuticals International pledged to Congress that it would offer hospitals breaks of as much as 30% on two of its expensive heart drugs, officials at the hospital figured they would hear from the company soon.

“I think we definitely would be among the top users,” said Scott Knoer, the chief pharmacy officer at the Cleveland Clinic. The two drugs, Nitropress and Isuprel, are commonly used to treat heart patients, and their prices shot up last year after Valeant acquired them. The clinic spent more than $5.3 million on the two drugs in 2015. “I would assume we would be on that list.”

Instead, there has been silence.

For more details, go to: http://www.nytimes.com/2016/05/12/business/valeant-promised-price-breaks-on-drugs-heart-hospitals-are-still-waiting.html?emc=edit_th_20160512&nl=todaysheadlines&nlid=20088616&_r=0